HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.

Abstract
Loss of function mutations in CCAAT/enhancer binding protein alpha (CEBPA) have been identified in acute myeloid leukemia (AML) and bi-allelic (double) CEBPA mutations are associated with improved prognosis in cases of cytogenetically normal-AML. In a subset of AML patients lacking CEBPA mutations, core promotor methylation of CEBPA has been described and is associated with a gene expression profile similar to the mutated cases including the expression of T cell associated genes such as CD7. However, the overall incidence and pattern of CEBPA mutations and core promoter methylation has not been thoroughly explored in a larger subset of AML with expression of CD7. Here we describe a simple and clinically deployable CEBPA promoter methylation test and the results of combined testing for CEBPA mutations and promoter methylation in 102 cases of AML, including 43 CD7+ cases. Overall, there were 5 methylated cases, 6 cases with double mutations, and 3 cases with single mutations. Significantly, 10 of 43 CD7+ cases (23%) had either methylated or double-mutated CEBPA. The CD7+ subset included all 5 methylated cases and 5 of the 6 cases with double mutations. All 3 cases with single mutations were CD7-. No case exhibited both hypermethylation and mutations. We find that promoter methylation accounts for half of those CD7+ cases with CEBPA dysregulating abnormalities. Furthermore, methylated cases and those with bi-allelic CEBPA mutations have similar phenotypic features including expression of CD7 and lack of co-incident NPM1 mutations. Our study suggests that methylation testing may be as important as mutation testing for identifying AML cases with CEBPA dysregulation and may be indicated in the routine prognostic workup of AML.
AuthorsPhilippe Szankasi, Albert K Ho, David W Bahler, Olga Efimova, Todd W Kelley
JournalLeukemia research (Leuk Res) Vol. 35 Issue 2 Pg. 200-7 (Feb 2011) ISSN: 1873-5835 [Electronic] England
PMID20970189 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • CCAAT-Enhancer-Binding Proteins
  • CEBPA protein, human
  • NPM1 protein, human
  • Nucleophosmin
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • CCAAT-Enhancer-Binding Proteins (genetics)
  • Cell Separation
  • CpG Islands (genetics)
  • DNA Methylation (genetics)
  • DNA Mutational Analysis
  • Female
  • Flow Cytometry
  • Gene Expression Profiling
  • Humans
  • Immunophenotyping
  • Leukemia, Myeloid, Acute (genetics)
  • Male
  • Middle Aged
  • Mutation (genetics)
  • Nucleophosmin
  • Phenotype
  • Polymerase Chain Reaction
  • Promoter Regions, Genetic (genetics)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: